{"id":{"repo_id":"milano","oai_identifier":"oai:air.unimi.it:2434/1019088"},"canonical_url":"https://search.dev.ndltd.org/etd/milano/oai:air.unimi.it:2434/1019088","repository":{"repo_id":"milano","name":"Università degli Studi di Milano","base_url":"https://air.unimi.it/oai/request"},"display":{"title":"TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES","abstract":"Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification","abstract_html":"Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification","abstract_has_math":false,"creators":["BISBAL LOPEZ, LYDIA"],"institution":"Università degli Studi di Milano","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["tutor: A. Dal Corso","C. Gennari ; coordinatore: D. Passarella","L. BISBAL LOPEZ","DAL CORSO, ALBERTO","PASSARELLA, DANIELE"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023-12-01","date_published":"2023-12-01","updated_at":"2026-07-27T20:18:48Z","subjects":["Immune-Stimulating Antibody Conjugate","Toll-Like Receptor","Resiquimod","Antibody Engineering","Prodrug","Self-Immolative Spacers","Settore CHIM/08 - Chimica Farmaceutica"],"languages":["eng"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["http://dx.doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","10.13130/bisbal-lopez-lydia_phd2023-12-01"],"render_values":[{"text":"http://dx.doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","href":"http://dx.doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","code":true},{"text":"10.13130/bisbal-lopez-lydia_phd2023-12-01","href":"https://doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2434/1019088","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["tutor: A. Dal Corso","C. Gennari ; coordinatore: D. Passarella","L. BISBAL LOPEZ","DAL CORSO, ALBERTO","PASSARELLA, DANIELE"]},{"key":"dc:creator","label":"Author","values":["BISBAL LOPEZ, LYDIA"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2023-12-01"]},{"key":"dc:publisher","label":"Institution","values":["Università degli Studi di Milano"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Immune-Stimulating Antibody Conjugate","Toll-Like Receptor","Resiquimod","Antibody Engineering","Prodrug","Self-Immolative Spacers","Settore CHIM/08 - Chimica Farmaceutica"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://hdl.handle.net/2434/1019088","http://dx.doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","10.13130/bisbal-lopez-lydia_phd2023-12-01"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification"]},{"key":"dc:title","label":"Title","values":["TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES"]}]}],"canonical_facts":{"dc:contributor":["tutor: A. Dal Corso","C. Gennari ; coordinatore: D. Passarella","L. BISBAL LOPEZ","DAL CORSO, ALBERTO","PASSARELLA, DANIELE"],"dc:creator":["BISBAL LOPEZ, LYDIA"],"dc:date":["2023-12-01"],"dc:description":["Different strategies have been proposed in order to achieve the targeted delivery of anticancer agents at the tumor site. Amongst the different delivery vehicles proposed, antibody drug conjugates (ADCs) have been especially successful in the clinic. Recently, the involvement of the immune system in cancer treatment has been exploited. Following this strategy, immune-stimulating antibody conjugates (ISACs) have emerged as a new class of ADCs which antitumor immune responses through the use of immunostimulatory drugs connected to monoclonal antibodies (mAbs) which serve as targeting units. Even though ISACs have already entered early phase clinical trials, they have demonstrated several drawbacks. In this thesis, the problems showed by 1st generation ISACs are tackled using diverse approaches, involving all parts of this class of constructs, from the antibody and linker design to the payload diversification"],"dc:identifier":["https://hdl.handle.net/2434/1019088","http://dx.doi.org/10.13130/bisbal-lopez-lydia_phd2023-12-01","10.13130/bisbal-lopez-lydia_phd2023-12-01"],"dc:language":["eng"],"dc:publisher":["Università degli Studi di Milano"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:subject":["Immune-Stimulating Antibody Conjugate","Toll-Like Receptor","Resiquimod","Antibody Engineering","Prodrug","Self-Immolative Spacers","Settore CHIM/08 - Chimica Farmaceutica"],"dc:title":["TUMOR-TARGETED RELEASE OF IMMUNOSTIMULATORY AGENTS: SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOQUINOLINE-BASED PRODRUGS AND ANTIBODY CONJUGATES"],"dc:type":["info:eu-repo/semantics/doctoralThesis"]},"updated_at":"2026-07-27T20:18:48Z"}